Dyadic Announces Publication of C1 Monoclonal Antibody... - The first trial using a C1 produced monoclonal antibody provides equivalent protection against SARS-CoV-2 in hamster and nonhuman primate models compared to monoclonal antibody produced in CHO.
JUPITER, Fla., March 26, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic” or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial protein production platforms today announced the online publication of the manuscript "Filamentous fungus-produced human monoclonal antibody provides protection against SARS-CoV-2 in hamster and nonhuman primate models" in Nature Communications (“Springer-Nature"), an international journal publishing peer-reviewed research in all fields of science and technology.
“These results demonstrate that the C1-expression system is promising as a technology platform for human monoclonal antibody (HuMab) development and production for preventive and therapeutic medicines,” said Prof. Albert Osterhaus of Hannover University of Veterinary Medicine, Germany and of CR2O, a Dutch CRO. "The study characterized the in vitro activity of a monoclonal antibody (mAb) produced by C1 cells (designated "HuMab 87G7") and demonstrated its protective efficacy for both prophylactic and therapeutic applications in hamsters and non-human primates without causing antibody-mediated enhanced virus replication. Those are significant findings, in the sense that the demonstration of HuMab 87G7 in animal models against SARS-CoV-2 provided protection, especially with the raising concerns related to emerging infectious diseases in a changing world.”
https://www.globenewswire.com/news-release/2024/03/26/2852344/0/en/Dyadic-Announces-Publication-of-C1-Monoclonal-Antibody-in-Nonhuman-Primate-Study-in-Nature-Communications.html